Misplaced Pages

This is an old revision of this page, as edited by Citation bot (talk | contribs) at 22:46, 26 November 2022 (Alter: chapter-url. URLs might have been anonymized. | Use this bot. Report bugs. | Suggested by BorgQueen | Category:Chemicals that do not have a ChemSpider ID assigned | #UCB_Category 214/851). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Galiximab is a monoclonal antibody designed for the treatment of B-cell lymphoma. As of September 2009, it is undergoing Phase III clinical trials. The drug is a chimeric antibody from Macaca irus and Homo sapiens.

References

1. Ebadi M, Sadeghi MA, Reddy NM, Rezaei N (2020). "Immunopathology and Immunotherapy of Non-Hodgkin Lymphoma". In Rezaei M (ed.). Cancer immunology: cancer immunotherapy for organ-specific tumors (Second ed.). Cham: Springer Nature. p. 178. ISBN 978-3-03-057949-4.
2. "Biogen Idec: Pipeline". Archived from the original on 2008-05-17. Retrieved 2009-09-24.
3. WHO Drug Information

External links

• Official website

This monoclonal antibody–related article is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

This antineoplastic or immunomodulatory drug article is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

• Drugs not assigned an ATC code
• Monoclonal antibodies
• Monoclonal antibody stubs
• Antineoplastic and immunomodulating drug stubs